KINSHASA (Reuters) - Congolese authorities have authorized clinical trials for four experimental Ebola treatments, which will allow researchers to collect valuable data about their effectiveness, the health ministry said on Saturday.
Health workers have already administered therapeutic treatments to more than 150 Ebola patients since August in an effort to contain the worst of Democratic Republic of Congo’s 10 outbreaks of the hemorrhagic fever since 1976.
But until now doctors have decided which treatment to use on a case-by-case basis. In the clinical trial, the choice of treatment will now be randomized.
Treatment will still be free of charge, the ministry added in a statement.
“Precious information about the effectiveness of the treatments obtained during the clinical trial will allow for the development of these treatments on a wider scale to save more lives,” the ministry said.
The four treatments are mAb114, which was developed by the U.S. government; ZMapp, an intravenous treatment made by Mapp Biopharmaceutical; Remdesivir, made by Gilead Sciences; and Regeneron’s REGN-EB3.
As of last weekend, 151 patients had received one of the four drugs. Of those, 76 had recovered, 44 had died and 31 were still hospitalized -- a mortality rate of 37 percent.
By contrast, among those who had not received treatment, the mortality rate was close to 80 percent.
The ministry said that the data from the current outbreak would probably not be sufficient to make definitive conclusions about the effectiveness of the treatments and that the trials could continue during future outbreaks.
Despite the use of the treatments as well as an experimental vaccine manufactured by Merck, authorities have struggled to contain the outbreak due to widespread militia violence in eastern Congo and community resistance to health workers.
At least 228 people are believed to have died, and the World Health Organization said last week that it expects the outbreak to last at least another six months.
Reporting By Giulia Paravicini; Editing by Aaron Ross
Our Standards: The Thomson Reuters Trust Principles.